支气管扩张症合并耐碳青霉烯类铜绿假单胞菌感染患者个体化治疗的药学实践  

The Pharmaceutical Practice of Individualized Treatment for Bronchiectasis Complicated with Carbapenem-resistant Pseudomonas Aeruginosa Infection

作　　者：陈芳辉[1] 付年程 魏桂林[1] CHEN Fanghui;FU Niancheng;WEI Guilin(The First Affiliated Hospital of Gannan Medical University,Ganzhou Jiangxi 341000,China;Fuzhou Linchuan People's Hospital,Fuzhou Jiangxi 344001,China)

机构地区：[1]赣南医学院第一附属医院,江西赣州341000 [2]抚州市临川区人民医院,江西抚州344001

出　　处：《药品评价》2021年第18期1115-1117,共3页Drug Evaluation

摘　　要：目的:探讨支气管扩张症合并耐碳青霉烯类铜绿假单胞菌感染患者的抗感染治疗策略。方法:1例青年支气管扩张症合并耐碳青霉烯类铜绿假单胞菌感染患者,临床药师根据患者病史、用药史及病原学结果,协助临床医师制订个体化抗感染治疗方案。结果:患者感染得到有效控制,同时节约了治疗费用。结论:对于病史特殊和广泛耐药细菌感染的患者,临床药师应积极参与药物治疗,提升治疗效果,促进合理用药。Objective:To explore the anti-infection treatment strategy for patients with bronchiectasis complicated with carbapenem-resistant Pseudomonas aeruginosa infection.Methods:A young patient with bronchiectasis complicated with carbapenem-resistant Pseudomonas aeruginosa infection was investigated.According to the patient’s medical history,drug use history and etiological results,the clinical pharmacist assisted the clinician to formulate an individualized anti-infection-treatment plan.Results:The infection of the patients was effectively controlled and the cost of treatment was saved.Conclusion:For patients with special medical history and extensively drug-resistant bacterial infection,clinical pharmacists should actively participate in drug therapy to improve the therapeutic effect and promote rational drug use.

关 键 词：支气管扩张症 耐碳青霉烯类铜绿假单胞菌 抗菌药物 临床药师 药学服务 

分 类 号：R969[医药卫生—药理学]